Article
Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Jun 2024
Pang Lanlan, Huang Yihua, Zhuang Weitao, Zhang Yaxiong, Liao Jun, Hao Yue, Hao Feng, Wang Guoqian, Chen Ze-Xin Chase, Zhu Yu, Li Mengzhen, Song Zhengbo, Deng Bo Peng, Li Jing, Zhang Li, Fang Wenfeng
Abstract excerpt
PURPOSE: The current National Comprehensive Cancer Network (NCCN) guidelines recommend afatinib or osimertinib as the preferred first-line treatment strategy for patients with advanced NSCLC harboring EGFR p.G719X mutation. However, in the absence of head-to-head trials comparing afatinib with osimertinib in EGFR p.G719X-mutant patients, it is unclear which regimen is the preferred treatment option. EXPERIMENTAL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.